Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11060345rdf:typepubmed:Citationlld:pubmed
pubmed-article:11060345lifeskim:mentionsumls-concept:C0023816lld:lifeskim
pubmed-article:11060345lifeskim:mentionsumls-concept:C0052191lld:lifeskim
pubmed-article:11060345lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:11060345lifeskim:mentionsumls-concept:C0205419lld:lifeskim
pubmed-article:11060345lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:11060345lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:11060345lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:11060345lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:11060345lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:11060345pubmed:issue11lld:pubmed
pubmed-article:11060345pubmed:dateCreated2000-11-29lld:pubmed
pubmed-article:11060345pubmed:abstractTextWe have identified a G-to-A transition in exon 3 of the APOC3 gene resulting in a novel Ala23Thr apolipoprotein (apo) C-III variant, associated with apoC-III deficiency in three unrelated Yucatan Indians. The Ala23Thr substitution modifies the hydrophobic/hydrophilic repartition of the helical N-terminal peptide and hence could disturb the lipid association. In vitro expression in Escherichia coli of wild-type and mutant apoC-III enabled the characterization of the variant. Compared with wild-type apoC-III-Ala23, the mutant apoC-III-Thr23 showed reduced affinity for dimyristoylphosphatidylcholine (DMPC) multilamellar vesicles with higher amounts of free apoC-III. Displacement of apoE from discoidal apoE:dipalmitoylphosphatidycholine (DPPC) complex by apoC-III-Thr23 was comparable to wild type but the less efficient binding of the apoC-III-Thr23 to the discoidal complex resulted in a higher apoE/apoC-III (mol/mol) ratio (34%) than with wild-type/apoE:DPPC mixtures. The inhibition of lipoprotein lipase (LPL) by apoC-III-Thr23 was comparable to that of wild type, and therefore effects on LPL activity could not explain the lower triglyceride (Tg) levels in Thr-23 carriers. Thus, these in vitro results suggest that in vivo the less efficient lipid binding of apoC-III-Thr23 might lead to a faster catabolism of free apoC-III, reflected in the reduced plasma apoC-III levels identified in Thr-23 carriers, and poorer competition with apoE, which might enhance clearance of Tg-rich lipoproteins and lower plasma Tg levels seen in Thr-23 carriers.lld:pubmed
pubmed-article:11060345pubmed:languageenglld:pubmed
pubmed-article:11060345pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11060345pubmed:citationSubsetIMlld:pubmed
pubmed-article:11060345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11060345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11060345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11060345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11060345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11060345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11060345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11060345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11060345pubmed:statusMEDLINElld:pubmed
pubmed-article:11060345pubmed:monthNovlld:pubmed
pubmed-article:11060345pubmed:issn0022-2275lld:pubmed
pubmed-article:11060345pubmed:authorpubmed-author:RosseneuMMlld:pubmed
pubmed-article:11060345pubmed:authorpubmed-author:LiuHHlld:pubmed
pubmed-article:11060345pubmed:authorpubmed-author:WeissK MKMlld:pubmed
pubmed-article:11060345pubmed:authorpubmed-author:BrasseurRRlld:pubmed
pubmed-article:11060345pubmed:authorpubmed-author:FerrellRRlld:pubmed
pubmed-article:11060345pubmed:authorpubmed-author:HumphriesS...lld:pubmed
pubmed-article:11060345pubmed:authorpubmed-author:LinzGGlld:pubmed
pubmed-article:11060345pubmed:authorpubmed-author:TalmudP JPJlld:pubmed
pubmed-article:11060345pubmed:authorpubmed-author:XuC FCFlld:pubmed
pubmed-article:11060345pubmed:authorpubmed-author:LabeurCClld:pubmed
pubmed-article:11060345pubmed:issnTypePrintlld:pubmed
pubmed-article:11060345pubmed:volume41lld:pubmed
pubmed-article:11060345pubmed:ownerNLMlld:pubmed
pubmed-article:11060345pubmed:authorsCompleteYlld:pubmed
pubmed-article:11060345pubmed:pagination1760-71lld:pubmed
pubmed-article:11060345pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:meshHeadingpubmed-meshheading:11060345...lld:pubmed
pubmed-article:11060345pubmed:year2000lld:pubmed
pubmed-article:11060345pubmed:articleTitleCharacterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr.lld:pubmed
pubmed-article:11060345pubmed:affiliationCardiovascular Genetics Division, Department of Medicine, Royal Free and University College London Medical School, London WC1E 6JJ, UK.lld:pubmed
pubmed-article:11060345pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11060345pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:345entrezgene:pubmedpubmed-article:11060345lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11060345lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11060345lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11060345lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11060345lld:pubmed